Suppr超能文献

合胞体突变不会损害糖蛋白D受体靶向性单纯疱疹病毒进入和传播的特异性。

Syncytial Mutations Do Not Impair the Specificity of Entry and Spread of a Glycoprotein D Receptor-Retargeted Herpes Simplex Virus.

作者信息

Okubo Yu, Uchida Hiroaki, Wakata Aika, Suzuki Takuma, Shibata Tomoko, Ikeda Hitomi, Yamaguchi Miki, Cohen Justus B, Glorioso Joseph C, Tagaya Mitsuo, Hamada Hirofumi, Tahara Hideaki

机构信息

Division of Bioengineering, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.

出版信息

J Virol. 2016 Nov 28;90(24):11096-11105. doi: 10.1128/JVI.01456-16. Print 2016 Dec 15.

Abstract

UNLABELLED

Membrane fusion, which is the key process for both initial cell entry and subsequent lateral spread of herpes simplex virus (HSV), requires the four envelope glycoproteins gB, gD, gH, and gL. Syncytial mutations, predominantly mapped to the gB and gK genes, confer hyperfusogenicity on HSV and cause multinucleated giant cells, termed syncytia. Here we asked whether interaction of gD with a cognate entry receptor remains indispensable for initiating membrane fusion of syncytial strains. To address this question, we took advantage of mutant viruses whose viral entry into cells relies on the uniquely specific interaction of an engineered gD with epidermal growth factor receptor (EGFR). We introduced selected syncytial mutations into gB and/or gK of the EGFR-retargeted HSV and found that these mutations, especially when combined, enabled formation of extensive syncytia by human cancer cell lines that express the target receptor; these syncytia were substantially larger than the plaques formed by the parental retargeted HSV strain. We assessed the EGFR dependence of entry and spread separately by using direct entry and infectious center assays, respectively, and we found that the syncytial mutations did not override the receptor specificity of the retargeted viruses at either stage. We discuss the implications of these results for the development of more effective targeted oncolytic HSV vectors.

IMPORTANCE

Herpes simplex virus (HSV) is investigated not only as a human pathogen but also as a promising agent for oncolytic virotherapy. We previously showed that both the initial entry and subsequent lateral spread of HSV can be retargeted to cells expressing tumor-associated antigens by single-chain antibodies fused to a receptor-binding-deficient envelope glycoprotein D (gD). Here we introduced syncytial mutations into the gB and/or gK gene of gD-retargeted HSVs to determine whether viral tropism remained dependent on the interaction of gD with the target receptor. Entry and spread profiles of the recombinant viruses indicated that gD retargeting does not abolish the hyperfusogenic activity of syncytial mutations and that these mutations do not eliminate the dependence of HSV entry and spread on a specific gD-receptor interaction. These observations suggest that syncytial mutations may be valuable for increasing the tumor-specific spreading of retargeted oncolytic HSV vectors.

摘要

未标记

膜融合是单纯疱疹病毒(HSV)初始细胞进入及随后横向传播的关键过程,需要四种包膜糖蛋白gB、gD、gH和gL。主要定位在gB和gK基因上的合胞体突变赋予HSV高融合性,并导致形成多核巨细胞,即合胞体。在这里,我们探讨了gD与同源进入受体的相互作用对于启动合胞体菌株的膜融合是否仍然不可或缺。为了解决这个问题,我们利用了突变病毒,其病毒进入细胞依赖于工程化gD与表皮生长因子受体(EGFR)的独特特异性相互作用。我们将选定的合胞体突变引入到EGFR靶向的HSV的gB和/或gK中,发现这些突变,尤其是组合时,能使表达靶受体的人癌细胞系形成广泛的合胞体;这些合胞体比亲本靶向HSV菌株形成的噬斑大得多。我们分别使用直接进入和感染中心试验来评估进入和传播对EGFR的依赖性,并且我们发现合胞体突变在任何一个阶段都没有超越靶向病毒的受体特异性。我们讨论了这些结果对于开发更有效的靶向溶瘤HSV载体的意义。

重要性

单纯疱疹病毒(HSV)不仅作为人类病原体被研究,还作为溶瘤病毒疗法的有前景的药物被研究。我们之前表明,HSV的初始进入和随后的横向传播都可以通过与缺乏受体结合的包膜糖蛋白D(gD)融合的单链抗体重新靶向到表达肿瘤相关抗原的细胞上。在这里,我们将合胞体突变引入到gD靶向的HSV的gB和/或gK基因中,以确定病毒嗜性是否仍然依赖于gD与靶受体的相互作用。重组病毒的进入和传播概况表明,gD重新靶向不会消除合胞体突变的高融合活性,并且这些突变不会消除HSV进入和传播对特定gD-受体相互作用的依赖性。这些观察结果表明,合胞体突变对于增加重新靶向的溶瘤HSV载体的肿瘤特异性传播可能是有价值的。

相似文献

5
A Strategy for Cultivation of Retargeted Oncolytic Herpes Simplex Viruses in Non-cancer Cells.
J Virol. 2017 Apr 28;91(10). doi: 10.1128/JVI.00067-17. Print 2017 May 15.

引用本文的文献

2
Novel mutations in U24 and gH rescue efficient infection of an HSV vector retargeted to TrkA.
Mol Ther Methods Clin Dev. 2023 Jul 3;30:208-220. doi: 10.1016/j.omtm.2023.06.012. eCollection 2023 Sep 14.
3
Cell Fusion and Syncytium Formation in Betaherpesvirus Infection.
Viruses. 2021 Sep 30;13(10):1973. doi: 10.3390/v13101973.
4
Potent anti-tumor effects of receptor-retargeted syncytial oncolytic herpes simplex virus.
Mol Ther Oncolytics. 2021 Aug 19;22:265-276. doi: 10.1016/j.omto.2021.08.002. eCollection 2021 Sep 24.
6
Entry of Alphaherpesviruses.
Curr Issues Mol Biol. 2021;41:63-124. doi: 10.21775/cimb.041.063. Epub 2020 Aug 7.

本文引用的文献

2
Designing Herpes Viruses as Oncolytics.
Mol Ther Oncolytics. 2015;2:15010-. doi: 10.1038/mto.2015.10. Epub 2015 Jul 22.
3
Interplay between the Herpes Simplex Virus 1 gB Cytodomain and the gH Cytotail during Cell-Cell Fusion.
J Virol. 2015 Dec;89(24):12262-72. doi: 10.1128/JVI.02391-15. Epub 2015 Sep 23.
4
Herpes simplex viral-vector design for efficient transduction of nonneuronal cells without cytotoxicity.
Proc Natl Acad Sci U S A. 2015 Mar 31;112(13):E1632-41. doi: 10.1073/pnas.1423556112. Epub 2015 Mar 16.
5
Development of a sensitive screening method for selecting monoclonal antibodies to be internalized by cells.
Biochem Biophys Res Commun. 2014 Nov 28;454(4):600-3. doi: 10.1016/j.bbrc.2014.10.133. Epub 2014 Nov 1.
7
Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma.
BMC Genomics. 2014 Mar 13;15(1):190. doi: 10.1186/1471-2164-15-190.
10
Enhanced antitumoral activity of oncolytic herpes simplex virus with gemcitabine using colorectal tumor models.
Int J Cancer. 2013 Apr 1;132(7):1592-601. doi: 10.1002/ijc.27823. Epub 2012 Sep 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验